Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 27-Feb-23 6:08 PM View:  | Appelhans Dannielle CEO and President | Rubius Therapeutics, Inc. (RUBY) | 24-Feb-23 | Sale | 10,385 | $0.13 | $1,323.05 | (100%) 10.38K to 0 | |
| 01-Feb-23 9:40 PM View: | Appelhans Dannielle CEO and President | Rubius Therapeutics, Inc. (RUBY) | 01-Feb-23 | Option Sale | 3,878 | $0.25 | $969.50 | (27%) 14.26K to 10.38K | |
| 01-Feb-23 9:41 PM View: | Cagnoni Pablo J Director | Rubius Therapeutics, Inc. (RUBY) | 01-Feb-23 | Sale | 8,448 | $0.25 | $2,112.00 | (11%) 74.53K to 66.08K | |
| 31-Jan-23 9:50 PM View: | Turka Laurence A. Chief Scientific Officer | Rubius Therapeutics, Inc. (RUBY) | 31-Jan-23 | Option Exercise | 8,625 | -- | -- | 70% 12.36K to 20.98K | |
| 31-Jan-23 9:51 PM View: | Cagnoni Pablo J Director | Rubius Therapeutics, Inc. (RUBY) | 31-Jan-23 | Option Sale | 7,240 | $0.24 | $1,744.84 | (9%) 81.77K to 74.53K | |
| 31-Jan-23 9:50 PM View: | Turka Laurence A. Chief Scientific Officer | Rubius Therapeutics, Inc. (RUBY) | 31-Jan-23 | Option Sale | 2,593 | $0.24 | $622.32 | (12%) 20.98K to 18.39K | |
| 31-Jan-23 9:51 PM View: | Cagnoni Pablo J Director | Rubius Therapeutics, Inc. (RUBY) | 31-Jan-23 | Option Exercise | 25,000 | -- | -- | 44% 56.77K to 81.77K | |
| 01-Feb-23 9:40 PM View: | Appelhans Dannielle CEO and President | Rubius Therapeutics, Inc. (RUBY) | 31-Jan-23 | Option Exercise | 7,500 | -- | -- | 111% 6.76K to 14.26K | |
| 31-Jan-23 9:51 PM View: | Cagnoni Pablo J Director | Rubius Therapeutics, Inc. (RUBY) | 29-Jan-23 | Option Exercise | 21,250 | -- | -- | 60% 35.52K to 56.77K | |
| 31-Jan-23 9:50 PM View: | Turka Laurence A. Chief Scientific Officer | Rubius Therapeutics, Inc. (RUBY) | 29-Jan-23 | Option Exercise | 7,438 | -- | -- | 151% 4.92K to 12.36K | |
| 12-Aug-22 3:06 PM View: | Appelhans Dannielle Chief Operating Officer | Rubius Therapeutics, Inc. (RUBY) | 10-Aug-22 | Option Sale | 5,737 | $0.80 | $4,589.60 | (46%) 12.5K to 6.76K | |
| 12-Aug-22 3:06 PM View: | Appelhans Dannielle Chief Operating Officer | Rubius Therapeutics, Inc. (RUBY) | 09-Aug-22 | Option Exercise | 12,500 | -- | -- | 100% 0 to 12.5K | |
| 22-Apr-22 6:07 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 21-Apr-22 | Private Purchase | 30,000 | $1.44 | $43,329.00 | < 1% 4.69M to 4.72M | |
| 01-Feb-22 9:20 PM View: | Cagnoni Pablo J CEO and President Director | Rubius Therapeutics, Inc. (RUBY) | 01-Feb-22 | Option Sale | 6,730 | $6.57 | $44,236.30 | (16%) 42.25K to 35.52K | |
| 01-Feb-22 9:19 PM View: | Keson-Brookes Maiken CLO & Corp. Secretary | Rubius Therapeutics, Inc. (RUBY) | 01-Feb-22 | Option Sale | 2,732 | $6.57 | $17,957.40 | (34%) 8.07K to 5.34K | |
| 01-Feb-22 9:18 PM View: | Turka Laurence A. Chief Scientific Officer | Rubius Therapeutics, Inc. (RUBY) | 01-Feb-22 | Option Sale | 2,517 | $6.57 | $16,544.20 | (34%) 7.44K to 4.92K | |
| 01-Feb-22 9:20 PM View: | Cagnoni Pablo J CEO and President Director | Rubius Therapeutics, Inc. (RUBY) | 29-Jan-22 | Option Exercise | 21,250 | -- | -- | 101% 21.0K to 42.25K | |
| 01-Feb-22 9:19 PM View: | Keson-Brookes Maiken CLO & Corp. Secretary | Rubius Therapeutics, Inc. (RUBY) | 29-Jan-22 | Option Exercise | 8,075 | -- | -- | 100% 0 to 8.07K | |
| 01-Feb-22 9:18 PM View: | Turka Laurence A. Chief Scientific Officer | Rubius Therapeutics, Inc. (RUBY) | 29-Jan-22 | Option Exercise | 7,438 | -- | -- | 100% 0 to 7.44K | |
| 14-Feb-22 10:00 PM View: | Cagnoni Pablo J CEO and President Director | Rubius Therapeutics, Inc. (RUBY) | 16-Jun-21 | Gift | 2,200 | -- | -- | (7%) 31.52K to 29.32K | |
| 14-Feb-22 10:00 PM View: | Cagnoni Pablo J CEO and President Director | Rubius Therapeutics, Inc. (RUBY) | 26-Apr-21 | Gift | 4,000 | -- | -- | (11%) 35.52K to 31.52K | |
| 23-Mar-21 5:30 PM View: | Flagship Ventures Fund Iv G... 10% Owner | Rubius Therapeutics, Inc. (RUBY) | 19-Mar-21 | Purchase | 210,000 | $29.00 | $6,090,000.00 | < 1% 38.3M to 38.51M | |
| 15-Mar-21 8:28 PM View: | Keson-Brookes Maiken CLO & Corp. Secretary | Rubius Therapeutics, Inc. (RUBY) | 15-Mar-21 | Option Exercise | 25,000 | $7.70 | $192,500.00 | 100% 0 to 25.0K | |
| 15-Mar-21 8:28 PM View: | Keson-Brookes Maiken CLO & Corp. Secretary | Rubius Therapeutics, Inc. (RUBY) | 15-Mar-21 | Market Option Sale (Planned) | 25,000 | $20.24 | $505,965.00 | (100%) 25.0K to 0 | |
| 16-Feb-21 9:51 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 11-Feb-21 | Market Sale (Planned) | 26,704 | $14.93 | $398,560.00 | (< 1%) 4.72M to 4.69M | 13% |
| 10-Feb-21 9:12 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 10-Feb-21 | Market Sale (Planned) | 7,404 | $14.79 | $109,525.00 | (< 1%) 4.72M to 4.72M | 3% |
| 10-Feb-21 9:12 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 09-Feb-21 | Market Sale (Planned) | 2,100 | $14.83 | $31,145.90 | (< 1%) 4.73M to 4.72M | 3% |
| 10-Feb-21 9:12 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 08-Feb-21 | Market Sale (Planned) | 89,233 | $14.88 | $1,328,120.00 | (2%) 4.82M to 4.73M | 3% |
| 19-May-20 8:02 PM View: | Oh Andrew M. Chief Financial Officer | Rubius Therapeutics, Inc. (RUBY) | 15-May-20 | Option Exercise | 5,000 | $4.74 | $23,700.00 | 100% 0 to 5.0K | |
| 24-Apr-20 4:13 PM View: | Coughlin Christina M. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 22-Apr-20 | Market Purchase | 19,000 | $5.52 | $104,814.00 | 100% 0 to 19.0K | 160% |
| 15-Apr-20 5:14 PM View: | Cagnoni Pablo J CEO and President Director | Rubius Therapeutics, Inc. (RUBY) | 14-Apr-20 | Market Purchase | 21,000 | $4.70 | $98,693.70 | 100% 0 to 21.0K | 205% |
| 19-Mar-20 6:34 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 17-Mar-20 | Market Purchase | 5,000 | $3.76 | $18,800.00 | < 1% 4.81M to 4.82M | 282% |
| 17-Mar-20 5:59 PM View: | Epstein David R Director | Rubius Therapeutics, Inc. (RUBY) | 13-Mar-20 | Market Purchase | 10,000 | $3.91 | $39,100.00 | < 1% 4.8M to 4.81M | 267% |
| 18-Dec-19 7:50 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 16-Dec-19 | Option Exercise | 48,000 | $2.87 | $137,760.00 | 138% 34.84K to 82.84K | |
| 18-Dec-19 7:50 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 16-Dec-19 | Market Option Sale (Planned) | 48,000 | $13.48 | $646,901.00 | (58%) 82.84K to 34.84K | (6%) |
| 17-Oct-19 6:01 AM View: | Langer Robert Director | Rubius Therapeutics, Inc. (RUBY) | 14-Oct-19 | Market Option Sale (Planned) | 7,500 | $8.52 | $63,874.50 | (100%) 7.5K to 0 | (68%) |
| 17-Oct-19 6:01 AM View: | Langer Robert Director | Rubius Therapeutics, Inc. (RUBY) | 14-Oct-19 | Option Exercise | 7,500 | $0.15 | $1,125.00 | 100% 0 to 7.5K | |
| 18-Sep-19 9:37 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 17-Sep-19 | Market Option Sale (Planned) | 11,877 | $10.05 | $119,309.00 | (25%) 46.72K to 34.84K | (43%) |
| 18-Sep-19 9:37 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 17-Sep-19 | Option Exercise | 11,877 | $2.87 | $34,087.00 | 34% 34.84K to 46.72K | |
| 18-Sep-19 9:37 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 16-Sep-19 | Market Option Sale (Planned) | 36,123 | $10.13 | $365,897.00 | (51%) 70.97K to 34.84K | (42%) |
| 18-Sep-19 9:37 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 16-Sep-19 | Option Exercise | 36,123 | $2.87 | $103,673.00 | 104% 34.84K to 70.97K | |
| 26-Jul-19 7:06 PM View: | Nissen Torben Straight President | Rubius Therapeutics, Inc. (RUBY) | 24-Jul-19 | Option Exercise | 207,146 | $0.18 | $37,607.70 | 11% 1.85M to 2.05M | |
| 17-Jul-19 4:14 PM View: | Langer Robert Director | Rubius Therapeutics, Inc. (RUBY) | 15-Jul-19 | Option Exercise | 7,500 | $0.15 | $1,125.00 | 100% 0 to 7.5K | |
| 17-Jul-19 4:14 PM View: | Langer Robert Director | Rubius Therapeutics, Inc. (RUBY) | 15-Jul-19 | Market Option Sale (Planned) | 7,500 | $14.94 | $112,048.00 | (100%) 7.5K to 0 | 4% |
| 24-Jun-19 6:02 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 20-Jun-19 | Option Exercise | 243 | $2.87 | $697.41 | < 1% 34.84K to 35.09K | |
| 24-Jun-19 6:02 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 20-Jun-19 | Market Option Sale (Planned) | 243 | $13.93 | $3,385.96 | (< 1%) 35.09K to 34.84K | (3%) |
| 19-Jun-19 9:39 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 19-Jun-19 | Market Option Sale (Planned) | 18,399 | $13.80 | $253,868.00 | (35%) 53.24K to 34.84K | (4%) |
| 19-Jun-19 9:39 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 19-Jun-19 | Option Exercise | 18,399 | $2.87 | $52,805.10 | 53% 34.84K to 53.24K | |
| 19-Jun-19 9:39 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 18-Jun-19 | Market Option Sale (Planned) | 10,858 | $14.27 | $154,958.00 | (24%) 45.7K to 34.84K | (< 1%) |
| 19-Jun-19 9:39 PM View: | Carpenter Christopher L. Chief Medical Officer | Rubius Therapeutics, Inc. (RUBY) | 18-Jun-19 | Option Exercise | 10,858 | $2.87 | $31,162.50 | 31% 34.84K to 45.7K |
